New combo therapy shows promise for rare sarcoma
NCT ID NCT03802071
First seen May 03, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tested a combination of the immunotherapy drug durvalumab with standard chemotherapy (doxorubicin) in 44 people with advanced soft tissue sarcoma that had spread or come back. The goal was to see if adding durvalumab could improve outcomes for this aggressive cancer, which typically has a survival of less than a year. The trial focused on safety and tolerability of the combination.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Severance Hospital, Yonsei University Health System
Seoul, 03722, South Korea
Conditions
Explore the condition pages connected to this study.